H84T-BanLec is derived from a carbohydrate-binding protein called lectin, isolated from bananas. H84T-BanLec binds to high-mannose glycans -- polysaccharides that are present on virus surfaces, but rarely on healthy human cells. After binding, the virus is effectively blocked from entering and infecting cells.

Atomic force microscopy helped the researchers confirm that H84T-BanLec develops multiple strong bonds with the spike protein, deterring lectin resistance. Therapeutic lectin use has previously been avoided, as it may stimulate the immune system in potentially harmful ways. However, when H84T-BanLec is modified to remove this effect, animal models show no detrimental effects.

Current COVID-19 treatments, including remdesivir, Paxlovid, and monoclonal antibodies, have varying side effects and effectiveness, particularly as SARS-CoV-2 evolves. The researchers contend that H84T-BanLec holds unique promise and hope to see its testing transition from animal models to humans. They also hope to investigate H84T-BanLec's effectiveness against cancer, since cancer cells, like viruses, also have high-mannose glycans on their surfaces.

"When COVID-19 occurred, we of course wanted to study the therapy's potential and discovered it was effective against every type of coronavirus, in vitro and in vivo," Dr. David Markovitz, internal medicine professor at the University of Michigan, said in a statement. "Whether delivered systemically or through the nose in animal models, or prophylactically or therapeutically early on in the illness, it worked."

Hope for next-gen COVID-19 vaccines may rest in an unexpected region of the virus
Researchers further elucidated how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible...

Vir touts research on SARS-CoV-2 host-cell entry, antibodies
Vir Biotechnology touted a preclinical study that highlights the mechanisms SARS-CoV-2 uses to enter host cells and identifies three new auxiliary receptors...

SARS-CoV-2 hijacks lung cells for its own purposes
The first map of molecular responses of human lung cells to SARS-CoV-2 infection has been developed. It shows that the novel coronavirus causes significant...

Validating drug repurposing workflows may help identify new COVID-19 treatments
A research team has strengthened COVID-19 drug repurposing workflows through independent in vitro validation followed by clinical pharmacology data assessments,...